Todd Foley - 02 Jun 2022 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: TRDA
Reported as of: 02 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jun 2022, 16:11:03 UTC
Prior SEC filing: 16 May 2022
Next SEC filing: 12 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Todd Foley

Key filing fact

Todd Foley filed Form 4 for Entrada Therapeutics, Inc. (TRDA) on 06 Jun 2022.

Key facts

This page summarizes Todd Foley's Form 4 filing for Entrada Therapeutics, Inc. (TRDA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 06 Jun 2022, 16:11.

Change

Previous filing in this sequence was filed on 16 May 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TRDA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +11,918
Change %
Price: $0.000000
Shares after: 11,918
Date: 02 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 11,918
Exercise price: $6.06
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 2, 2022 (the "Vesting Start Date") or (ii) the Issuer's next annual meeting of stockholders.